SHORT-TERM ECONOMIC AND CLINICAL OUTCOMES OF CANAGLIFLOZIN COMPARED TO SITAGLIPTIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS (T2DM)

Author(s)

Lopez JM1, Martin S1, Ektare V2, Patel D3, Rupnow MF1, Botteman MF2
1Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Pharmerit International, Bethesda, MD, USA, 3Pharmerit North America LLC, Bethesda, MD, USA

OBJECTIVES: Short-term cost per outcome analyses focusing on efficient attainment of desired healthcare outcomes, including quality measures can be useful decision-making tools for managed-care payers. Therefore, a simple cost-efficiency model was developed to compare the short-term (i.e., 1-year) clinical and economic outcomes of treating hyperglycemia with canagliflozin versus sitagliptin in people with T2DM. METHODS: Data on clinical efficacy and key adverse events (AEs) were obtained from a pooled analysis of 2 comparative trials of canagliflozin 300 mg/day versus sitagliptin100 mg/day. Wholesale drug acquisition costs were used. The total and diabetes-related cost savings associated with achieving (vs. not achieving) A1C<7% was specified as $3,055/year and $1,651/year, respectively, based on  previously reported claims database analysis. Savings of $288/year associated with 1% decrease in weight, sourced from the literature was applied. AE-related costs (i.e., $105-$154/genital mycotic infections and $532/hypoglycemia requiring third-party assistance) were derived from treatment algorithms, literature, and reimbursement rates. Total costs, average and incremental costs/key outcomes were calculated. RESULTS: In the simplest analysis evaluating drug cost/outcome only, where annual drug-related costs were similar (canagliflozin 300 mg $3,660 vs sitagliptin $3,594), the average cost/patient achieving A1C<7% were lower for canagliflozin 300 mg compared to sitagliptin ($7,162 vs $8,398/patient per year, respectively). Likewise, the average cost per 1% reduction in A1C were lower for canagliflozin 300 mg versus sitagliptin ($3,893 vs $5,364).  In a comprehensive analysis including medical, drug, and adverse event costs, canagliflozin 300 mg dominates sitagliptin in incremental cost efficiency in A1C goals.  Canagliflozin 300 mg resulted in net savings of $639 per patient / year compared to sitagliptin.  CONCLUSIONS: Based on inputs and assumptions used in this model, this 52-week economic analysis suggests that canagliflozin 300mg is likely to be a cost-saving treatment option compared with sitagliptin 100 mg when used in combination with other antihyperglycemic agents to treat T2DM.

Conference/Value in Health Info

2014-05, ISPOR 2014, Palais des Congres de Montreal

Value in Health, Vol. 17, No. 3 (May 2014)

Code

PDB77

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Diabetes/Endocrine/Metabolic Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×